JAMA Cardiology

SEPTEMBER 30, 2021

This cohort study examines the prevalence of epicardial coronary artery disease and coronary microvascular dysfunction in hospitalized patients with heart failure with preserved ejection fraction.

Coronary Artery Disease 40

Coronary Artery Disease Preserved Ejection Fraction Heart Failure Hospital 40

The American Journal of Cardiology

JANUARY 10, 2024

Publication date: 15 February 2024 Source: The American Journal of Cardiology, Volume 213 Author(s): Mingqiang Fu, Yanyan Wang, Xueting Han, Shuai Yuan, Yuan Liu, Juying Qian, Jingmin Zhou, Junbo Ge

Preserved Ejection Fraction 40

Preserved Ejection Fraction Coronary Artery Disease Heart Failure 40

DAIC

APRIL 3, 2024

Featured topics will include in-depth sessions covering non-statin lipid lowering therapies, heart failure with preserved ejection fraction, viability, imaging modalities for the assessment of coronary artery disease, and antiplatelet therapy after coronary stenting. Too Many Choices?

Education 105

Education Preserved Ejection Fraction Coronary Artery Disease Cardio Oncology 105

Circulation: Heart Failure

DECEMBER 18, 2023

BACKGROUND:Coronary microvascular dysfunction (CMD) is involved in heart failure (HF) onset and progression, independently of HF phenotype and obstructive coronary artery disease. CMD was invasively assessed by continuous intracoronary thermodilution and defined as coronary flow reserve <2.5.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Coronary Artery Disease Circulation 40

Frontiers in Cardiovascular Medicine

AUGUST 6, 2024

In the long term, a history of gestational hypertension and pre-eclampsia significantly increases the risk of future cardiovascular disease including chronic hypertension, coronary artery disease, heart failure and stroke.

Heart Failure 40

Heart Failure Preserved Ejection Fraction Coronary Artery Disease Hypertension 40

Cardiometabolic Health Congress

JULY 25, 2023

4] More recently, at least at the epidemiologic level, the obesity paradox has been confirmed in both heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF), but also in those with coronary heart disease. [5, International Journal of Obesity 38.8

Obesity 52

Obesity BMI Heart Failure Cardiovascular Disease 52

Cardiology Update

APRIL 9, 2024

STEP-HFpEF DM 5 ( NCT04916470 ) explored the effects of semaglutide in obesity-related HF with preserved ejection fraction (HFpEF) and type 2 diabetes. The results advocate for considering PCI as a treatment option for such plaques, potentially expanding the indications for PCI in coronary artery disease management.

Angina 52

Angina Myocardial Infarction Aortic valve Coronary Artery Disease 52